Form 4: TriSalus CFO Granted Equity Awards

TriSalus Life Sciences' Chief Financial Officer, David Patience, was granted 65,000 restricted stock units and 130,000 employee stock options.

Summary

• David Patience, Chief Financial Officer of TriSalus Life Sciences, Inc. (TLSI), was granted equity awards.
• The awards include 65,000 restricted stock units (RSU Award) and 130,000 employee stock options.
• The RSU Award was granted at a price of $0 on November 24, 2025, and vests in four equal annual installments commencing on November 24, 2025, subject to continued employment.
• The employee stock options were granted on November 24, 2025, have an exercise price of $5.55, and expire on November 23, 2035.
• Vesting for the options begins with one-fourth on the one-year anniversary of November 24, 2025, followed by 1/36th of the remaining shares each month thereafter, subject to continued employment.
• Following these transactions, Mr. Patience beneficially owns 265,000 shares of common stock and 668,899 derivative securities.

Sentiment

Score: 7

Explanation: The filing reports a standard executive compensation event, which is generally positive as it aligns management's interests with shareholders. No negative or unexpected information is present.

Positives

• The grant of equity awards to the Chief Financial Officer aligns management's interests with long-term shareholder value.
• The structured vesting schedules for both Restricted Stock Units and stock options incentivize continued employment and performance, promoting executive retention.

Future Outlook

The multi-year vesting schedules for the equity awards indicate an expectation of the CFO's continued employment and a long-term focus on value creation for the company.

Industry Context

This is a routine executive compensation disclosure, common across industries for publicly traded companies to incentivize and retain key personnel. It reflects standard practices for aligning executive interests with shareholder value through equity grants.

Comparison to Industry Standards

• The grant of restricted stock units and stock options to a Chief Financial Officer is a standard component of executive compensation packages in publicly traded companies, particularly within the life sciences sector.
• Vesting schedules tied to continued employment over several years are typical, aiming to retain talent and encourage long-term performance, comparable to practices at peers in the biotechnology and pharmaceutical industries.
• The exercise price of $5.55 for options is common, often set at the market price on the grant date, aligning with fair market value compensation practices for executive incentives.

Related Party Transactions

• The grant of restricted stock units and employee stock options to David Patience, the Chief Financial Officer, constitutes a related party transaction as it involves compensation provided by the company to a key executive.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the CFO's interests with long-term company performance. Future dilution from share issuance upon RSU vesting and option exercise is a consideration.
• Employees: May signal stability in executive leadership and a commitment to long-term incentives within the company.

Next Steps

• Continued employment of the CFO through the respective vesting dates for both RSUs and stock options.
• Future annual vesting of RSU awards commencing November 24, 2025.
• Future monthly vesting of stock options commencing one year after November 24, 2025.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to the Chief Financial Officer, which is a standard component of executive compensation. While it aligns management's interests with shareholders, it does not present new information that would fundamentally alter the investment thesis or warrant a change in an existing position. It is a neutral event for immediate stock price movement.

Keywords

TriSalus Life Sciences, TLSI, David Patience, CFO, Form 4, Restricted Stock Units, RSU, Stock Options, Equity Grant, Insider Ownership, Executive Compensation